Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Other Non-Current Liabilities (2019 - 2021)

SRx Health Solutions (SRXH) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $17.0 million as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Other Non-Current Liabilities rose 285.84% year-over-year to $17.0 million, compared with a TTM value of $17.0 million through Jun 2021, up 285.84%, and an annual FY2020 reading of $39.8 million, up 3522.73% over the prior year.
  • Other Non-Current Liabilities was $17.0 million for Q2 2021 at SRx Health Solutions, down from $46.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $46.3 million in Q1 2021 and bottomed at $200000.0 in Q1 2020.
  • Average Other Non-Current Liabilities over 3 years is $13.7 million, with a median of $2.8 million recorded in 2019.
  • The sharpest move saw Other Non-Current Liabilities tumbled 33.33% in 2020, then soared 23066.5% in 2021.
  • Year by year, Other Non-Current Liabilities stood at $1.1 million in 2019, then skyrocketed by 3522.73% to $39.8 million in 2020, then crashed by 57.4% to $17.0 million in 2021.
  • Business Quant data shows Other Non-Current Liabilities for SRXH at $17.0 million in Q2 2021, $46.3 million in Q1 2021, and $39.8 million in Q4 2020.